Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes

Remco van Horssen, Alexander M.M. Eggermont, Timo L.M. ten Hagen

Research output: Contribution to journalShort surveypeer-review

45 Citations (Scopus)

Abstract

Endothelial monocyte-activating polypeptide-II (EMAP-II) is a pro-inflammatory cytokine with anti-angiogenic properties. Its precursor, proEMAP, is identical to the p43 auxiliary component of the tRNA multisynthetase complex and therefore involved in protein translation. Although most of the activities have been ascribed to the active form EMAP-II, also p43 has reported cytokine properties. ProEMAP/p43 and EMAP-II act on many levels and on many cell types including endothelial cells, immune cells and fibroblasts. In this review we summarize all available data on isolation, expression and functions of EMAP-II both in physiological processes as well as in pathological settings, like cancer. We also discuss the different reported mechanisms for processing of proEMAP/p43 into EMAP-II. Finally, we speculate on the possible applications of this cytokine for (cancer) therapy.

Original languageEnglish
Pages (from-to)339-348
Number of pages10
JournalCytokine and Growth Factor Reviews
Volume17
Issue number5
DOIs
Publication statusPublished - Oct 2006
Externally publishedYes

Keywords

  • Angiogenesis
  • Apoptosis
  • EMAP-II
  • Inflammation
  • p43

Fingerprint

Dive into the research topics of 'Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes'. Together they form a unique fingerprint.

Cite this